Abstract
INTRODUCTION: Treatment of hypersensitivity pneumonitis involves removal of the antigen and may include the use of immunosuppression or antifibrotic therapy. It remains unclear whether antifibrotic or immunosuppressive therapy is more beneficial in fibrotic hypersensitivity pneumonitis or if clinical markers can predict a patient's response to therapy. METHODS: We evaluated a retrospective cohort in order to determine if certain clinical characteristics can predict physiologic improvement with immunosuppressive treatment in patients with chronic hypersensitivity pneumonitis. Patients with a diagnosis of hypersensitivity pneumonitis with a moderate, high, or definite confidence according to the American Thoracic Society criteria were included in the study. RESULTS: Overall immunosuppression did not lead to improvement in % predicted forced vital capacity (FVC%) and % predicted diffusion capacity (DLCO%). Patients with fibrotic hypersensitivity pneumonitis and those with familial interstitial lung disease demonstrated a decline in FVC% predicted as well as DLCO% predicted over one year and the use of immunosuppression does not modify that risk. In contrast, patients with extensive ground glass demonstrated improvement in DLCO% predicted but not FVC% predicted over one year with or without the use of immunosuppression. CONCLUSION: Our study demonstrates that certain radiographic variables trend toward a significant impact on FVC% predicted as well as DLCO% predicted and suggests that antifibrotic therapy may be a better initial choice of therapy in patients with fibrotic hypersensitivity pneumonitis as decline occurred with or without the use of immunosuppression.